New compounding pharmacy company backed by Bain

A new company financed by Bain Capital intends to stake a position in the sterile compounding market. QuVa Pharma has started by acquiring an FDA 503B registered compounding facility in Sugar Land, TX, from Helix. Terms of the deal were not disclosed. QuVa was founded by Stuart Hinchen, who is CEO, and Peter Jenkins, who is chief development officer. Both executives bring to QuVa Pharma the experience from time at JHP Pharmaceuticals and Mayne Pharma, the company said in a release. "With the support of Bain Capital Private Equity, we will be able to aggressively pursue an expansion strategy," Hinchen said in a statement. The FDA started the registration program for compounding pharmacies last year as part of the Drug Quality and Security Act. Release | More

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.

Lonza will build two new manufacturing suites at its Visp, Switzerland site to handle antibody-drug conjugates for an unnamed customer.